Shares in Corin lost almost half their value after the company warned that full-year profits would be “materially below” analysts’ current estimates.

The medical device maker said that sales of Cormet, its hip-resurfacing technology, had been lower than expected, and that Stryker, its US partner for the development and marketing of the treatment, would not be placing more orders until the second quarter of 2009.